20/20 Biolabs, Inc. 10-K filing
Filed 2026-03-31 · Report date 2025-12-31 · 2025 FY
Filing metadata
- Accession number
- 0001213900-26-037667
- Form type
- 10-K
- CIK
- 0001139685
- Primary document
- https://www.sec.gov/Archives/edgar/data/1139685/000121390026037667/ea0283134-10k_2020bio.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for 20/20 Biolabs, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $2.0M | - | - |
| Cost Of Revenue | $1.4M | - | - |
| Gross Profit | $604,541 | - | - |
| Operating Income | $-3.3M | - | - |
| Net Income | $-3.7M | - | - |
| Eps Basic | -0.76 | - | - |
| Eps Diluted | -0.76 | - | - |
| Cash And Equivalents | $1.0M | - | - |
| Total Assets | $4.1M | - | - |
| Total Liabilities | $4.2M | - | - |
| Shareholders Equity | $-19,225 | - | - |
| Operating Cash Flow | $-1.9M | - | - |